WO2002039973A2 - Product preparing and protecting the skin against uv radiation, countering cellular ageing and exerting an immunostimulant action - Google Patents

Product preparing and protecting the skin against uv radiation, countering cellular ageing and exerting an immunostimulant action Download PDF

Info

Publication number
WO2002039973A2
WO2002039973A2 PCT/FR2001/003626 FR0103626W WO0239973A2 WO 2002039973 A2 WO2002039973 A2 WO 2002039973A2 FR 0103626 W FR0103626 W FR 0103626W WO 0239973 A2 WO0239973 A2 WO 0239973A2
Authority
WO
Grant status
Application
Patent type
Prior art keywords
characterized
product according
mg
carotene
β
Prior art date
Application number
PCT/FR2001/003626
Other languages
French (fr)
Other versions
WO2002039973A3 (en )
Inventor
Jean-Christophe Anton
Sylvie Chantereau
Robert Schwartz
Original Assignee
Laboratoires Robert Schwartz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/04Preparations for care of the skin for chemically tanning the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/31Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toilet preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/673Vitamin B group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/676Ascorbic acid, i.e. vitamin C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/30Cosmetics or similar toilet preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/678Tocopherol, i.e. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K8/00Cosmetics or similar toilet preparations
    • A61K8/18Cosmetics or similar toilet preparations characterised by the composition
    • A61K8/96Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toilet preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92Oral administration

Abstract

The invention concerns a product for oral administration for simultaneously protecting the skin against UV radiation, protecting it against cellular ageing processes and for exerting an immunostimulant action, and based on a combination of β-carotene, at least a flavonoid and vitamins. The invention is characterised in that the β-carotene is associated with catechins.

Description

Preparing product and protecting the skin against UV rays, acting counter to the cellular aging and exerting an immunostimulating Action

The present invention relates to a product can be administered orally in conjunction to the preparation and the protection of the skin against UV radiation, protection against cellular aging mechanisms, and exert a parallel immunostimulating action. This product is mainly based on β-carotene association, at least one flavonoid and various vitamins. already known products comprising this association, especially for preparing the skin has a momentarily most intense exposure to solar radiation, both before and during a stay in a region with plenty of sunshine.

For example, there capsules to take a few days before and during exposure to said radiation and which contain a β-carotene association of vitamins C and E and flavonoids.

In general, multiple products available in pharmacy or drugstore certainly aim to protect the skin, but also to accelerate tanning, tanned skin sparking a craze and meet current aesthetic criteria. They are all in this effect based on carotenoids, including β-carotene is one example.

Carotenoids have a direct protective role, since they act as a filter or screen. They also have a skin color function (yellow-orange) imitating the natural tan. The vitamins that are added, usually mainly vitamins C and E have antioxidant power and therefore oppose the skin aging process.

Finally, the tanning preparation products possess more generally essential fatty acids, which act on the hydration of the epidermis. Specifically, the carotenoids are used in the body mainly for their antioxidant function in plasma (especially in relation to circulating lipids), but also in the cells as they are incorporated into the membranes. The β-carotene, in particular, is subject to a conversion mechanism because it is the precursor of vitamin A. It is therefore highly susceptible reactions processing or use before his arrival at the skin, which of course greatly reduces its interest as a component in preparation of products and tanning or protecting the skin, in which it is primarily useful in the skin, where it is used as a pigment and antioxidant.

In fact, the above products would be much more effective if we manage to control the location of the use of β-carotene, and in particular to curb consumption in the plasma to allow it to happen in larger quantities at the skin.

The main objective of the invention is to solve this problem, by optimizing for a specific goal the use of β-carotene in the body, to protect and prepare the skin against UV radiation, against the mechanisms of cell aging, and finally to promote an immunostimulatory action.

To meet these objectives, the product of the invention is mainly characterized in that the β-carotene is associated with catechins.

It was indeed found that catechins are delaying the use of β- carotene in plasma. Indeed, a catechin supplementation slows the one hand the reduction of β-carotene levels, and decreases on the other hand the level of use in plasma. This finding results from experiments using green tea, which we realized that the regular intake possible to reach blood levels of catechins may contribute to engage in an activity described above. The β-carotene can then arrive in greater quantities in the skin, since less used in plasma, its antioxidant function being performed by some types of catechins.

In other words, if we want that supplementation with β-carotene in the skin to be effective, it must be accompanied by a supplementation catechins.

Preferably, the β-carotene used for supplementation is type isomeric all-trans.

The shape of all-trans β-carotene is indeed absorbed faster than the other known isomeric form, the 9-cis form. It is becoming less degraded theory in the gastrointestinal tract than the latter, and its serum concentration is thus superior.

Finally, all-trans isomeric form is more strongly absorbed regardless of the type of administration, single or repeated dose. It has therefore optimal bioavailability due to its particular molecular and physico-chemical state. Supplementation with β-carotene all-trans therefore guarantees maximum efficiency, in particular to meet the above objectives.

Preferably, the β-carotene is used more synthetic. The latter, for example, is indeed much better absorbed than β- carotene plant, which is likely "trapped" within the chloroplasts, and probably then undergoes complexation phenomenon with the proteins of these cells. The absorption of β-carotene deficiency plant could also be the result of his physical condition in vegetables. In carrots, for example, it is in the form of microcrystals, which probably will not have time to gastrointestinal transit necessary for their solubilization. This shaped microcrystals is weakly bioavailable compared to synthetic β-carotene.

The goal is to achieve optimum serum and tissue concentrations of β-carotene supplementation should therefore be made in summary form rather than a food intake increases naturally containing β-carotene. According to the invention, the β-carotene is present in an amount by weight of between 2 mg and 50 mg.

Specifically, that product may comprise 14 mg, tests have shown that this value is used to achieve optimization of the amount administered / therapeutic effect ratio. According to one possibility, the catechins that are associated according to the invention the β-carotene are present in a weight amount between 25 mg and 600 mg.

Specifically, the product of the invention comprises 250 mg, this value being regarded as an average value resulting in good experimental results.

Preferably, the catechins used include mainly catechins epigallocatechin gallate and epicatechin gallate such kind.

Studies have indeed catechins classified according to their ability to delay the decrease in plasma concentration of β-carotene oxidation condition.

In order of decreasing activity, and specifically for the β-carotene, catechins are classified as follows: epigallocatechin gallate, epicatechin gallate, epigallocatechin, and with much less interesting effects, epicatechin and catechin. It is therefore functionally better to use the first two

The product of the invention further comprises, as mentioned previously, a combination of vitamins E and vitamin C.

It is known that vitamin E is the main antioxidant in the body tissues. It protects cell membranes at an early stage of the radical attack by its ability to trap free radicals. It is considered the first line of defense against lipid peroxidation. Free radicals, when they are not captured by an anti-oxidant, attack the polyunsaturated fatty acids of cell membranes in a chain reaction. However, these free radicals are apparently involved in the development of a number of diseases and degenerative conditions such as coronary heart disease, cancer, Alzheimer's disease, arthritis, premature aging, cataracts, etc. ..

A decreased concentration of vitamin E causes a so peroxidation higher rate of fat which contributes largely to the aging process and the development of diseases associated with said aging. In particular, vitamin E has a protective effect of skin aging by decreasing the level of expression of collagenase, induced by environmental stress and aging. In addition, vitamin E has an immunostimulatory action because it fights the reduction action of the immune defense of the body.

In the invention, vitamin E is combined with vitamin C as this combination produces a synergistic effect on the induced protection. This effect is a notable example on skin inflammation caused by solar radiation.

Note that the β-carotene Association / Vitamin E is also interesting because it causes a synergy that leads to more effective protection against erythema especially due to UV exposure.

According to one possibility, the vitamin E is present in the product of the invention in a weight amount between 2 mg and 20 mg, vitamin C y being present in a weight amount between 20 mg and 200 mg.

Preferably said product comprises more precisely 10 mg of vitamin E and 120 mg of vitamin C. Generalizing, the product may contain an ascorbic acid combination /

D-alpha-tocopherol, one of the stereoisomers of vitamin E. This combination is as previously necessary due to the synergistic effect on the induced protection equivalent to that mentioned above. This effect comes again reinforce the protective action of β-carotene. The product of the invention also contains vitamin B5. This vitamin is the precursor of coenzyme A, its main component, and acts as such in the metabolism of lipids, carbohydrates and proteins. She is involved in the synthesis of steroid hormones derived from cholesterol and in the synthesis of heme in hemoglobin. This vitamin also promotes the growth and resistance of the skin and mucous membranes, and is beneficial against the effects of UV because it calms signs of irritation and redness due to its healing properties. According to one possibility, the vitamin B5 is present in an amount by weight of between 2 and 12 mg. Preferably, the product of the invention comprises in fact 6 mg.

The product of the invention may also comprise, besides the catechins, flavonoids other, one of the major properties is that they are able to scavenge radicals formed in various circumstances.

But although their role physiological or incompletely studied, it is assumed that said radicals are responsible for alterations of nucleic acids and mutation, initiation and promotion of cancer process, and cellular damage because such , their reaction with membrane phospholipids.

In addition, flavonoids are enzyme inhibitors, anti-inflammatory or anti-allergic.

Like vitamin B5, flavonoids are therefore an important active product of the invention, including enhancing vascular resistance, and to reduce edema and redness caused by UV radiation.

The product of the invention and defined by its essential components, may of course be envisaged in various galenic forms, preferably for oral administration. According to a preferred possibility, it is in the form of a beverage consisting:

- rich in flavonoids cranberry juice;

- fructose;

- inulin; - extract rich in catechins plant;

- vitamins C, E and B5;

- β-carotene; and

- aromas.

Other packaging for oral administration are also possible, as evidenced by the following two examples.

It is thus possible to package said product in the form of capsules made of gelatin coat or plant shell and containing the following components:

- extract rich in catechins plant; - vitamins C, E and B5; and

- β-carotene.

Alternatively, this product may be in the form of capsules with a gelatin coat, and consist of: - yellow wax;

- oil ;

- extract rich in catechins plant;

- vitamins C, E and B5;

- β-carotene; and - lecithin.

Finally, the invention may be provided in the form of a preparation for beverages, such as infusions, be incorporated for this purpose with a carrier such as sucrose, maltodextrin or inulin, and include:

- extract rich in catechins plant; - vitamins C, E and B5; and

- the β-carotene.

In all these packages, according to the invention, the extract rich in catechins plant consists for example of green tea extract.

Of course, the above examples are not restrictive of the invention, which encompasses the contrary, including packaging variations and substitutions of components that are within the skill of the art.

Claims

1. Product orally administrable jointly to the preparation and the protection of the skin against UV radiation, protection against cellular aging mechanisms and exert an immunostimulatory action, based on a β-carotene association, at least one flavonoid and vitamins, characterized in that the β-carotene is associated with catechins.
2. Product according to the preceding claim, characterized in that the β- carotene is used isomeric type all-trans.
3. Product according to the preceding claim, characterized in that the β- carotene used is synthetic.
4. Product according to any one of the preceding claims, characterized in that the β-carotene is present in an amount by weight of between 2 mg and 50 mg.
5. Product according to the preceding claim, characterized in that it comprises 14 mg of β-carotene.
6. Product according to any one of the preceding claims, characterized in that catechins are present in a weight amount between 25 mg and 600 mg.
7. Product according to the preceding claim, characterized in that it comprises 250 mg of catechins.
8. Product according to any one of the preceding claims, characterized in that the catechins used include catechins epigallocatechin gallate and epicatechin gallate such kind.
9. Product according to any one of the preceding claims, characterized in that it comprises a combination of vitamins E and vitamin C.
10. Product according to the preceding claim, characterized in that the vitamin E is present in a weight amount between
2 mg and 20 mg, and vitamin C is present in a weight amount between 20 mg and 200 mg.
11. Product according to the preceding claim, characterized in that it comprises 10 mg of vitamin E and 120 mg of vitamin C.
12. A product according to any one of claims 1 to 8, characterized in that it contains a combination ascorbic acid / D-alpha-tocopherol.
13. A product according to any preceding claim, characterized in that it contains vitamin B5.
14. Product according to any one of the preceding claims, characterized in that the vitamin B5 is present in an amount by weight of between 2 and 12 mg.
15. Product according to the preceding claim, characterized in that it comprises 6 mg of vitamin B5.
16. A product according to any preceding claim, characterized in that it is in the form of a beverage consisting:
- rich in flavonoids cranberry juice;
- fructose; - inulin;
- plant extract riôhe catechins;
- vitamins C, E and B5;
- β-carotene; and
- aromas.
17. Product according to any one of claims 1 to 15, characterized in that it is in the form of capsules made of gelatin coat or plant shell and containing the following components:
- extract rich in catechins plant;
- vitamins C, E and B5; and - β-carotene.
18. Product according to any one of claims 1 to 15, characterized in that it is in the form of capsules with a gelatin coat, and consist of:
- yellow wax; - oil ;
- extract rich in catechins plant;
- vitamins C, E and B5;
- β-carotene; and
- lecithin.
19. Product according to any one of claims 1 to 15, characterized in that it is in the form of a preparation for beverages, such as infusions, consisting of a carrier such as sucrose, maltodextrin or inulin, and comprising:
- extract rich in catechins plant; - vitamins C, E and B5; and
- the β-carotene.
20. Product according to any one of claims 16 to 19, characterized in that the extract rich in catechins plant consists of green tea extract.
PCT/FR2001/003626 2000-11-20 2001-11-19 Product preparing and protecting the skin against uv radiation, countering cellular ageing and exerting an immunostimulant action WO2002039973A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR00/14974 2000-11-20
FR0014974A FR2816839B1 (en) 2000-11-20 2000-11-20 PREPARING product and protecting the skin against UV rays, acting has against cellular aging and exerting an immunostimulatory action

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2199302A AU2199302A (en) 2000-11-20 2001-11-19 Product preparing and protecting the skin against uv radiation, countering cellular ageing and exerting an immunostimulant action

Publications (2)

Publication Number Publication Date
WO2002039973A2 true true WO2002039973A2 (en) 2002-05-23
WO2002039973A3 true WO2002039973A3 (en) 2002-07-25

Family

ID=8856678

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/003626 WO2002039973A3 (en) 2000-11-20 2001-11-19 Product preparing and protecting the skin against uv radiation, countering cellular ageing and exerting an immunostimulant action

Country Status (2)

Country Link
FR (1) FR2816839B1 (en)
WO (1) WO2002039973A3 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2851916A1 (en) * 2003-03-05 2004-09-10 Oreal Use of at least one catechu polyphenol in a composition aiding natural pigmentation of the skin or skin eruptions or lesions useful for increasing the perfusion of cutaneous blood, and for prevention or diminishing of canities
WO2004080380A2 (en) * 2003-03-05 2004-09-23 L'oreal Use of catechuic polyphenols for preparing compositions for stimulating a skin's natural pigmentation
EP2070513A1 (en) * 2002-12-16 2009-06-17 Henkel AG & Co. KGaA Antioxidant combinations with 6,7 disubstituted 2.2-dialkylchromanes or chromenes
CN100548266C (en) 2004-01-24 2009-10-14 荷兰联合利华有限公司 Skin lightening compositions
US20110207806A1 (en) * 2003-04-04 2011-08-25 Unigen, Inc. Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care
US8771761B2 (en) 2006-10-12 2014-07-08 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria
US9061039B2 (en) 2002-03-01 2015-06-23 Unigen, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US9168242B2 (en) 2002-03-22 2015-10-27 Unigen, Inc. Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia
US9370544B2 (en) 2002-04-30 2016-06-21 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2855755B1 (en) * 2003-06-05 2007-09-07 Oreal Use of at least one filter of the blue light to preserve the capital carotenoids endogenous skin; New filters blue light; cosmetic compositions

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290605A (en) * 1989-06-29 1994-03-01 Niva Shapira Sun-exposure nutritional supporting composition
EP0659402A2 (en) * 1993-12-21 1995-06-28 INDENA S.p.A. Formulations containing carotenoids and procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
US5925348A (en) * 1996-02-23 1999-07-20 Medical Doctor's Research Institute, Inc. Methods utilizing compositions containing sacred lotus (methyltransferase) to treat aging skin
WO1999048386A1 (en) * 1998-03-24 1999-09-30 Stueckler Franz Natural substance based agent
US5976568A (en) * 1997-02-21 1999-11-02 Medical Doctors' Research Institute, Inc. Modular system of dietary supplement compositions for optimizing health benefits and methods

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290605A (en) * 1989-06-29 1994-03-01 Niva Shapira Sun-exposure nutritional supporting composition
EP0659402A2 (en) * 1993-12-21 1995-06-28 INDENA S.p.A. Formulations containing carotenoids and procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
US5925348A (en) * 1996-02-23 1999-07-20 Medical Doctor's Research Institute, Inc. Methods utilizing compositions containing sacred lotus (methyltransferase) to treat aging skin
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
WO1998033494A1 (en) * 1997-02-04 1998-08-06 Kosbab John V Compositions and methods for prevention and treatment of vascular degenerative diseases
US5976568A (en) * 1997-02-21 1999-11-02 Medical Doctors' Research Institute, Inc. Modular system of dietary supplement compositions for optimizing health benefits and methods
WO1999048386A1 (en) * 1998-03-24 1999-09-30 Stueckler Franz Natural substance based agent

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9061039B2 (en) 2002-03-01 2015-06-23 Unigen, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US9168242B2 (en) 2002-03-22 2015-10-27 Unigen, Inc. Isolation of a dual COX-2 and 5-lipdxygenase inhibitor from Acacia
US9849152B2 (en) 2002-04-30 2017-12-26 Unigen, Inc. Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent
US9655940B2 (en) 2002-04-30 2017-05-23 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
US9370544B2 (en) 2002-04-30 2016-06-21 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent
EP2070513A1 (en) * 2002-12-16 2009-06-17 Henkel AG & Co. KGaA Antioxidant combinations with 6,7 disubstituted 2.2-dialkylchromanes or chromenes
WO2004080380A3 (en) * 2003-03-05 2004-10-21 Albert Duranton Use of catechuic polyphenols for preparing compositions for stimulating a skin's natural pigmentation
WO2004080380A2 (en) * 2003-03-05 2004-09-23 L'oreal Use of catechuic polyphenols for preparing compositions for stimulating a skin's natural pigmentation
FR2851916A1 (en) * 2003-03-05 2004-09-10 Oreal Use of at least one catechu polyphenol in a composition aiding natural pigmentation of the skin or skin eruptions or lesions useful for increasing the perfusion of cutaneous blood, and for prevention or diminishing of canities
US20110207806A1 (en) * 2003-04-04 2011-08-25 Unigen, Inc. Formulation of dual cycloxygenase (cox) and lipoxygenase (lox) inhibitors for mammal skin care
US9622964B2 (en) 2003-04-04 2017-04-18 Unigen, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US8790724B2 (en) * 2003-04-04 2014-07-29 Unigen, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
CN100548266C (en) 2004-01-24 2009-10-14 荷兰联合利华有限公司 Skin lightening compositions
US8771761B2 (en) 2006-10-12 2014-07-08 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria
US9623068B2 (en) 2006-10-12 2017-04-18 Unigen, Inc. Composition for treating atopic dermatitis comprising extracts of bamboo and scutellaria

Also Published As

Publication number Publication date Type
WO2002039973A3 (en) 2002-07-25 application
FR2816839B1 (en) 2003-09-26 grant
FR2816839A1 (en) 2002-05-24 application

Similar Documents

Publication Publication Date Title
US6313169B1 (en) Lutein esters having high bioavailability
US5904924A (en) Green nutritional powder composition
US6048566A (en) Non-alcoholic beverage and process of making
US6573299B1 (en) Method and compositions for treatment of the aging eye
US6440464B1 (en) Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US20020107292A1 (en) Primary composition comprising a lipophilic bioactive compound
US20100021573A1 (en) Compositions and methods for the prevention of cardiovascular disease
US20070085059A1 (en) Bioactive Complexes Compositions and Methods of Use Thereof
US20040023894A1 (en) Synergistic antioxidant combination of delta tocols and polyphenols
US20050266018A1 (en) Nutraceutical compositions with mangosteen
US20060003947A1 (en) Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US20090263367A1 (en) Composition and method for promoting internal health and external appearance
US20070082064A1 (en) Nutritional or dietary supplement for the treatment of macular degeneration
US20060115556A1 (en) Nutritional supplement drink containing xanthone extracts
US20050249821A1 (en) Nutritional supplement for treatment of ocular diseases
US20030104090A1 (en) Supplements containing annatto extracts and carotenoids and methods for using the same
WO2001017374A1 (en) Compositions comprising conjugated linoleic acid (cla)
US20070141170A1 (en) Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
WO2005041996A1 (en) Lotus and methyl donors
WO1997039632A1 (en) Natural antioxidant composition
US20050106219A1 (en) Primary composition comprising a lipophilic bioactive compound
JPH07196534A (en) Formulation containing carotenoid or procarotenoid combined with polyphenol in prevention of damage due to abnormal production of free radical
WO1999018814A1 (en) Preparation for the enhancement of the antioxidant status of cells
Çetin et al. Role of grape seed extract on methotrexate induced oxidative stress in rat liver
WO2004026287A1 (en) Orally administrable composition for improving skin quality

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
WWW Wipo information: withdrawn in national office

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: JP